ivermectin oral / Generic mfg. 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


«12...919293949596979899100101...129130»
  • ||||||||||  ivermectin / Generic mfg.
    Journal:  Utilizing eco-friendly kaolinite-biochar composite adsorbent for removal of ivermectin in aqueous media. (Pubmed Central) -  Jan 14, 2021   
    Though KPC showed better efficiency in adsorption capacity and lowering concentration in low-concentration solutions, KPA exhibited better reusability with 83.5 and 67.5% initial adsorption strengths remaining in the second and third adsorption cycles, respectively, compared to the 73.8 and 58.8% for the KPC. These results indicate that KPA and KPC composites have the economic potential for application in water treatment processes.
  • ||||||||||  dexamethasone / Generic mfg., ceftriaxone / Generic mfg.
    Clinical, Clinical data, Retrospective data, Journal:  Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection. (Pubmed Central) -  Jan 14, 2021   
    We conclude that early ambulatory (not hospitalized, treated at home), multidrug therapy is safe, feasible, and associated with low rates of hospitalization and death. Early treatment should be considered for high-risk patients as an emergency measure while we await randomized trials and guidelines for ambulatory management.
  • ||||||||||  ritonavir / Generic mfg.
    Journal:  Interactions of Potential Anti-COVID-19 Compounds with Multispecific ABC and OATP Drug Transporters. (Pubmed Central) -  Jan 14, 2021   
    Our in vitro studies, using a variety of model systems, explored the interactions of the antimalarial agents chloroquine and hydroxychloroquine; the antihelmintic ivermectin; and the proposed antiviral compounds ritonavir, lopinavir, favipiravir, and remdesivir with the ABCB1/Pgp, ABCG2/BCRP, and ABCC1/MRP1 exporters, as well as the organic anion-transporting polypeptide (OATP)2B1 and OATP1A2 uptake transporters. The results presented here show numerous pharmacologically relevant transporter interactions and may provide a warning on the potential toxicities of these repurposed drugs, especially in drug combinations at the clinic.
  • ||||||||||  Copegus (ribavirin) / Bausch Health
    Review, Journal:  Can Zn Be a Critical Element in COVID-19 Treatment? (Pubmed Central) -  Jan 13, 2021   
    Again, the effectiveness of Zn can be enhanced by using chloroquine as an ionophore while Zn inside the infected cell can stop SARS-CoV-2 replication. Given those benefits, this perspective paper describes how and why Zn could be given due consideration as a complement to the prescribed treatment of COVID-19.
  • ||||||||||  ivermectin oral / Generic mfg.
    Trial primary completion date:  Study in COvid-19 Patients With iveRmectin (CORVETTE-01) (clinicaltrials.gov) -  Jan 12, 2021   
    P2,  N=240, Recruiting, 
    Given those benefits, this perspective paper describes how and why Zn could be given due consideration as a complement to the prescribed treatment of COVID-19. Trial primary completion date: Dec 2020 --> Mar 2021
  • ||||||||||  ivermectin / Generic mfg.
    Journal:  Assessing Hypoendemic Onchocerciasis in Loa loa Endemic Areas of Southeast Nigeria. (Pubmed Central) -  Jan 12, 2021   
    Under the control program, ivermectin mass drug administration (MDA) focused only on hyper/meso-endemic local government areas (LGAs) identified by Rapid Epidemiological Mapping of Onchocerciasis as having ≥ 20% nodule rates...Mass drug administration targets for the same area varied tenfold by threshold chosen, from one LGA (population to be treated 221,935) to 13 LGAs (population 2,426,987). Because the Ov16 threshold selected will have considerable cost and resource implications, the decision to initiate MDA should incorporate entomological data demonstrating onchocerciasis transmission.